PKC-412 |
CGP-41251 |
NVP-PKC412 |
MIDOSTAURIN |
RYDAPT |
PKC412 |
BENZOYLSTAUROSPORINE |
4'-N-BENZOYLSTAUROSPORINE |
CGP 41251 |
N-BENZOYLSTAUROSPORINE |
PKC 412 |
CGP 41231 |
drugbank:06595 |
chembl:CHEMBL608533 |
pubchem.compound:9829523 |
chemidplus:120685-11-2 |
rxcui:1919083 |
Drug Class | Kinase Inhibitors |
FDA Approval | not approved |
Drug Class | Small molecule |
Drug Indications | antineoplastic agent |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Approval Status | Phase III |
Response Type | resistant |
combination therapy | Azacitidine + Midostaurin |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | Protein kinase C (PKC) inhibitor |
Direct Interaction | yes |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Indication/Tumor Type | mast-cell leukemia |
Response Type | predicted – sensitive |
Approval Status | Preclinical - Patient cell culture |
inhibitor (inhibitory) |
Mechanism of Interaction | Protein kinase C (PKC) inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Protein kinase C (PKC) inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Protein kinase C (PKC) inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Protein kinase C (PKC) inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Protein kinase C (PKC) inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Protein kinase C (PKC) inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Protein kinase C (PKC) inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Protein kinase C (PKC) inhibitor |
Direct Interaction | yes |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | Platelet-derived growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Protein kinase C (PKC) inhibitor |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Platelet-derived growth factor receptor inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | Protein kinase C (PKC) inhibitor |
Direct Interaction | yes |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Vascular endothelial growth factor receptor 2 inhibitor |
MIDOSTAURIN | Generic Name |
Drug Class | Kinase Inhibitors |
Drug Indications | antineoplastic agent |
Drug Class | Small molecule |
FDA Approval | not approved |
C1872 | NCI drug code |
CHEMBL608533 | ChEMBL Drug ID |
D07NVU | TTD Drug ID |